Drug Development and Clinical Network
Gerhard Gründer is a psychiatrist and psychopharmacologist. In OVID he acts as a shareholder and CEO. In his main place of employment, he is the Head of the Department of Molecular Neuroimaging at the Central Institute of Mental Health (University of Heidelberg). Formerly, he was the Professor of Experimental Neuropsychiatry at the Uniklinik RWTH Aachen. Gerhard Gründer is leading the first German psilocybin depression study at the CIMH Mannheim with 144 patients in two study centers.